BR112012018843B8 - radioimunoconjugado que se liga a cd37 humano, composição farmacêutica e kit para a produção do radioimunoconjugado - Google Patents
radioimunoconjugado que se liga a cd37 humano, composição farmacêutica e kit para a produção do radioimunoconjugadoInfo
- Publication number
- BR112012018843B8 BR112012018843B8 BR112012018843A BR112012018843A BR112012018843B8 BR 112012018843 B8 BR112012018843 B8 BR 112012018843B8 BR 112012018843 A BR112012018843 A BR 112012018843A BR 112012018843 A BR112012018843 A BR 112012018843A BR 112012018843 B8 BR112012018843 B8 BR 112012018843B8
- Authority
- BR
- Brazil
- Prior art keywords
- radioimmunoconjugate
- binds
- human
- kit
- production
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29952410P | 2010-01-29 | 2010-01-29 | |
| NO20100143A NO331080B1 (no) | 2010-01-29 | 2010-01-29 | Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav |
| US61/299,524 | 2010-01-29 | ||
| NO20100143 | 2010-01-29 | ||
| PCT/EP2011/051231 WO2011092295A2 (en) | 2010-01-29 | 2011-01-28 | Novel radioimmunoconjugates and uses thereof |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| BR112012018843A2 BR112012018843A2 (pt) | 2017-10-17 |
| BR112012018843A8 BR112012018843A8 (pt) | 2017-12-19 |
| BR112012018843B1 BR112012018843B1 (pt) | 2020-09-24 |
| BR112012018843B8 true BR112012018843B8 (pt) | 2020-12-22 |
Family
ID=44319900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012018843A BR112012018843B8 (pt) | 2010-01-29 | 2011-01-28 | radioimunoconjugado que se liga a cd37 humano, composição farmacêutica e kit para a produção do radioimunoconjugado |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US8628749B2 (https=) |
| EP (2) | EP2705857B1 (https=) |
| JP (2) | JP5646652B2 (https=) |
| KR (2) | KR101758409B1 (https=) |
| CN (2) | CN104338154B (https=) |
| AU (1) | AU2011209441B2 (https=) |
| BR (1) | BR112012018843B8 (https=) |
| CA (1) | CA2786655C (https=) |
| DK (2) | DK2528627T3 (https=) |
| ES (2) | ES2592402T3 (https=) |
| HR (1) | HRP20140538T1 (https=) |
| IL (2) | IL221091A (https=) |
| MX (2) | MX342539B (https=) |
| NO (1) | NO331080B1 (https=) |
| NZ (1) | NZ601055A (https=) |
| PH (2) | PH12012501516A1 (https=) |
| PL (1) | PL2528627T3 (https=) |
| PT (1) | PT2528627E (https=) |
| RS (1) | RS53346B (https=) |
| RU (2) | RU2560587C9 (https=) |
| SG (1) | SG182685A1 (https=) |
| SI (1) | SI2528627T1 (https=) |
| UA (1) | UA108631C2 (https=) |
| WO (1) | WO2011092295A2 (https=) |
| ZA (1) | ZA201205007B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014014258A2 (pt) * | 2011-12-13 | 2020-10-27 | Nordic Nanovector As. | molécula de anticorpo que se liga a cd37 humano; anticorpo; molécula de dna; vetor de expressão; célula hospedeira; método para produzir um anticorpo; composição farmacêutica; método de esgotamento de células b que expressam cd37 dentre uma população de células; radioimunoconjugado que se liga a cd37 humano; método de tratamento de uma malignidade de célula b; kit para a produção do radioimunoconjugado; e preparação injetável de anticorpo hh1 quimérico ou humanizado para uso no pré-tratamento de uma malignidade de célula b |
| HK1202156A1 (en) * | 2012-03-30 | 2015-09-18 | Immunogen, Inc. | Methods for increasing efficacy of cd37-based therapy |
| CN103933575B (zh) * | 2013-01-23 | 2017-09-29 | 上海新理念生物医药科技有限公司 | 一种三齿型连接子及其应用 |
| BR112015030457A2 (pt) * | 2013-06-07 | 2017-08-22 | Nordic Nanovector As | Método para regular positivamente a expressão de antígeno |
| JP6510518B2 (ja) | 2013-08-01 | 2019-05-08 | アジェンシス，インコーポレイテッド | Ｃｄ３７タンパク質に結合する抗体薬物結合体（ａｄｃ） |
| CA2980462C (en) * | 2015-04-07 | 2023-08-01 | The Curators Of The University Of Missouri | Nanoparticle immunoconjugates |
| GB201600328D0 (en) * | 2016-01-08 | 2016-02-24 | Univ Oslo Hf | Anti-CD37 chimeric antigen receptors and immune cells expressing them |
| SG11201901672RA (en) * | 2016-09-16 | 2019-03-28 | Nordic Nanovector Asa | Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetan |
| KR102406510B1 (ko) | 2017-07-03 | 2022-06-10 | 현대자동차주식회사 | 연료전지 시스템용 수소 공급 방법 |
| CN109550061A (zh) * | 2017-09-26 | 2019-04-02 | 南京江原安迪科正电子研究发展有限公司 | 一种用于放射性核素标记抗体的试剂盒及应用 |
| CN111372613A (zh) * | 2017-11-22 | 2020-07-03 | 诺帝克纳诺维科特公司 | 放射免疫缀合物与其他药物联合治疗非霍奇金淋巴瘤 |
| SG11202110287QA (en) | 2019-04-24 | 2021-10-28 | Heidelberg Pharma Res Gmbh | Amatoxin antibody-drug conjugates and uses thereof |
| US20220211885A1 (en) * | 2019-04-25 | 2022-07-07 | Actinium Pharmaceuticals, Inc. | Compositions and methods of immunodepletion for the treatment of malignant and non-malignant hematological diseases |
| CN117241832A (zh) * | 2021-03-19 | 2023-12-15 | 海德堡医药研究有限责任公司 | B淋巴细胞特异性的鹅膏毒素抗体缀合物 |
| WO2023057595A1 (en) | 2021-10-06 | 2023-04-13 | Nordic Nanovector Asa | Humanized hh1 rew |
| EP4412715A1 (en) | 2021-10-06 | 2024-08-14 | Nordic Nanovector ASA | Humanized hh1 |
| CN114081969A (zh) * | 2021-11-23 | 2022-02-25 | 成都纽瑞特医疗科技股份有限公司 | 标记的小分子抗体、及其标记方法和应用 |
| CN117285631A (zh) * | 2023-11-24 | 2023-12-26 | 原子高科股份有限公司 | 用于放射性免疫治疗的Lu-177标记MUC1抗体 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5595721A (en) * | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| US20020028178A1 (en) * | 2000-07-12 | 2002-03-07 | Nabil Hanna | Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
| AU5914201A (en) * | 2000-04-25 | 2001-11-07 | Idec Pharma Corp | Intrathecal administration of rituximab for treatment of central nervous system lymphomas |
| JP2006511532A (ja) * | 2002-12-13 | 2006-04-06 | ミトラ、メディカル、テクノロジー、アクチボラグ | 三官能性試薬によって連結された、エフェクター機能および親和性機能を有する抗リンパ腫ターゲティング剤 |
| US7534427B2 (en) * | 2002-12-31 | 2009-05-19 | Immunomedics, Inc. | Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins |
| CN1767860A (zh) * | 2003-01-31 | 2006-05-03 | 免疫医疗公司 | 施用治疗和诊断剂的方法和组合物 |
| WO2005084179A2 (en) * | 2003-12-01 | 2005-09-15 | Immunomedics, Inc. | Improved method for preparing conjugates of proteins and chelating agents |
| HRP20140338T1 (hr) * | 2005-07-25 | 2014-06-20 | Emergent Product Development Seattle, Llc | Smanjenje broja b-stanica upotrebom molekula koje se specifiäśno vežu na cd37 i cd20 |
| PE20140196A1 (es) * | 2007-08-09 | 2014-03-19 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
-
2010
- 2010-01-29 NO NO20100143A patent/NO331080B1/no not_active IP Right Cessation
-
2011
- 2011-01-28 JP JP2012550464A patent/JP5646652B2/ja not_active Expired - Fee Related
- 2011-01-28 UA UAA201208485A patent/UA108631C2/ru unknown
- 2011-01-28 MX MX2015000391A patent/MX342539B/es unknown
- 2011-01-28 RU RU2012135430/10A patent/RU2560587C9/ru active
- 2011-01-28 EP EP13195682.3A patent/EP2705857B1/en active Active
- 2011-01-28 PT PT117009720T patent/PT2528627E/pt unknown
- 2011-01-28 EP EP11700972.0A patent/EP2528627B1/en active Active
- 2011-01-28 ES ES13195682.3T patent/ES2592402T3/es active Active
- 2011-01-28 BR BR112012018843A patent/BR112012018843B8/pt not_active IP Right Cessation
- 2011-01-28 DK DK11700972.0T patent/DK2528627T3/da active
- 2011-01-28 HR HRP20140538AT patent/HRP20140538T1/hr unknown
- 2011-01-28 SG SG2012054607A patent/SG182685A1/en unknown
- 2011-01-28 US US13/522,678 patent/US8628749B2/en active Active
- 2011-01-28 AU AU2011209441A patent/AU2011209441B2/en not_active Ceased
- 2011-01-28 WO PCT/EP2011/051231 patent/WO2011092295A2/en not_active Ceased
- 2011-01-28 DK DK13195682.3T patent/DK2705857T3/en active
- 2011-01-28 RU RU2015127407A patent/RU2664475C1/ru active
- 2011-01-28 SI SI201130157T patent/SI2528627T1/sl unknown
- 2011-01-28 KR KR1020127020917A patent/KR101758409B1/ko not_active Expired - Fee Related
- 2011-01-28 NZ NZ601055A patent/NZ601055A/en not_active IP Right Cessation
- 2011-01-28 CA CA2786655A patent/CA2786655C/en active Active
- 2011-01-28 PH PH1/2012/501516A patent/PH12012501516A1/en unknown
- 2011-01-28 MX MX2012008695A patent/MX2012008695A/es active IP Right Grant
- 2011-01-28 CN CN201410353070.5A patent/CN104338154B/zh active Active
- 2011-01-28 PL PL11700972T patent/PL2528627T3/pl unknown
- 2011-01-28 ES ES11700972.0T patent/ES2469140T3/es active Active
- 2011-01-28 CN CN201180007272.9A patent/CN102762230B/zh not_active Expired - Fee Related
- 2011-01-28 RS RS20140300A patent/RS53346B/sr unknown
- 2011-01-28 KR KR1020177018914A patent/KR101893720B1/ko not_active Expired - Fee Related
-
2012
- 2012-07-04 ZA ZA2012/05007A patent/ZA201205007B/en unknown
- 2012-07-24 IL IL221091A patent/IL221091A/en active IP Right Grant
-
2013
- 2013-12-09 US US14/100,756 patent/US9358309B2/en active Active
-
2014
- 2014-11-05 JP JP2014225005A patent/JP5855209B2/ja active Active
-
2015
- 2015-03-02 IL IL237507A patent/IL237507A0/en active IP Right Grant
-
2017
- 2017-06-05 PH PH12017501038A patent/PH12017501038B1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012018843B8 (pt) | radioimunoconjugado que se liga a cd37 humano, composição farmacêutica e kit para a produção do radioimunoconjugado | |
| UY32427A (es) | Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma | |
| MX358514B (es) | Compuestos para tratar la atrofia muscular espinal. | |
| BR112015023001A2 (pt) | composição de salto de exon para tratamento de distrofia muscular | |
| ECSP14017269A (es) | Compuestos para tratar la atrofia muscular espinal | |
| BR112013022927A2 (pt) | composição, métodos para substituir ou suplementar ou modificar uma microbiota do cólon de um sujeito, e para tratar um sujeito, e, uso de uma composição | |
| BRPI0905733B8 (pt) | composição, formulação farmacêutica, método para a produção de uma composição farmacêutica e uso de uma formulação farmacêutica | |
| BR112012008854A2 (pt) | combinação, kit de combinação, uso de uma combinação, composição farmacêutica, e, método para tratar câncer em um ser humano | |
| MX2015006234A (es) | Uso de akkermansia para tratar trastornos metabolicos. | |
| BR112014021531A2 (pt) | composto, composição farmacêutica e usos dos mesmos | |
| CO6511271A2 (es) | Compuestos de imidazopiridinil-aminopiridina sustituida | |
| UY32456A (es) | Composicion famaceutica, forma farmaceutica, procedimiento para su preparación, metodos de tratamiento | |
| CR20110466A (es) | Anticuerpos biespecíficos anti-erbb-3/anti-c-met | |
| GB201118656D0 (en) | New compounds | |
| BRPI0916286B8 (pt) | amidofenóxi-indazóis úteis como inibidores de c-met, seus usos, e composição farmacêutica | |
| BR112014021104A2 (pt) | métodos e composições para o tratamento da doença de huntington | |
| PH12013502565A1 (en) | Substituted imidazopyridinyl-aminopyridine compounds | |
| BR112012016129A2 (pt) | composto, composição, e, métodos para inibir a atividade de c-met, e para tratar câncer | |
| EA201591178A1 (ru) | Улучшенные композиции для пропускания экзона для лечения мышечной дистрофии | |
| BRPI0618577A8 (pt) | Usos de rituximab | |
| MX356755B (es) | Compuestos de tipo fumagilol y metodos para su elaboración y uso. | |
| CR20130602A (es) | Compuestos novedosos como inhibidores de diacilglicerol aciltransferasa | |
| EP2714048A4 (en) | SUBSTITUTED 2-BENZYLIDENE-2H-BENZO- [B -] [1,4-] THIAZIN-3- (4H-) ONE, DERIVATIVES THEREOF AND THERAPEUTIC APPLICATIONS THEREOF | |
| BR112012022337A2 (pt) | composição e respectivos método de preparação e uso de quantidade eficaz | |
| BR112013017953A2 (pt) | Composição farmacêutica, formulação tópica, método, e, composição fotossensibilizadora |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B65X | Notification of requirement for priority examination of patent application | ||
| B65Y | Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117) | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/01/2011, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REF. RPI 2594 DE 24/09/2020 QUANTO AO TITULO. |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 13A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2759 DE 21-11-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |